How to get peptides, and who pays

The most common peptide question after 'does it work' is 'how do I get it.' Those are not the same question. The first is answered by trials. The second is answered by a prescription, a benefit design, a compounding statute, or a seller who has already told you the product is not for human use.

Start with the labeled product

If the peptide is an approved medicine, the legal path is a licensed clinician and a pharmacy. Semaglutide is Ozempic, Wegovy, or Rybelsus — three products, two indications, different pens. Tirzepatide is Mounjaro or Zepbound. Tesamorelin is Egrifta for a narrow HIV-lipodystrophy label. Teriparatide is an osteoporosis anabolic with a duration cap. Insulin is a century of analog and human formulations. Oxytocin is an obstetric infusion. Bremelanotide is Vyleesi, not a tanning-forum PT-141 vial.

Compounded copies of those approved GLP-1s filled a shortage. When FDA declared the shortages resolved, compounding copies of the approved products generally stopped being allowed except in narrow 503A/503B cases. A compounded salt is not the trial product. FDA has said so in public.

What insurance is actually doing

• Indication is the switch. Ozempic for type 2 diabetes is a different benefit from Wegovy for obesity, even when the molecule is semaglutide.
• Prior authorization is normal: BMI cutoffs, A1c, step therapy. A denial is a contract, not a diagnosis.
• Medicare: incretins for diabetes have been a Part D question for years. From 1 July 2026 through 31 December 2027, the Medicare GLP-1 Bridge covers Wegovy (injection or tablet), Zepbound KwikPen, and Foundayo at $50 per month for eligible Part D members. Single-dose Zepbound vials and pens are out of that program.
• Specialty drugs (tesamorelin, teriparatide, Scenesse) run through hubs and duration caps.
• Research chemicals have no NDC. There is no claim.

Category 2 is not a rumor

In 2023 FDA placed a set of peptide bulk substances in Category 2 of its compounding interim policy — significant safety risks, including immunogenicity from aggregates and impurities, unnatural amino acids that complicate characterization, and thin human safety data. Ipamorelin acetate, kisspeptin-10, GHRP-2, and GHRP-6 remain on that safety-risk list as of this writing. A published IV ipamorelin study reported serious adverse events including death; FDA cites it.

In April 2026 FDA removed several peptide nominations from Category 2 and scheduled a Pharmacy Compounding Advisory Committee meeting. On 23–24 July 2026 the committee narrowly recommended six substances (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) for the 503A bulks list and rejected emideltide. FDA staff had recommended against all seven. A PCAC vote is not a listing. It is not an NDA. It does not sterilize a research vial.

What the grey market is

Lyophilized powder, a rubber stopper, a label that says not for human consumption, a reconstitution video. That is the product. Independent testing of adjacent research-chemical markets has found wrong identity, under-dosing, and contamination. Falsified Ozempic-like pens have been seized in the US. Bacterial contamination of multi-use vials is how people get abscesses from a 'healing' shot. WADA prohibits GH secretagogues, GH fragments, and thymosin beta-4 — a research vial is a sanction for a tested athlete.

Strand will not name vendors, quote a research-chemical dose, or turn this essay into a shopping guide. The access page on this site walks the four channels, the insurance rules, and the failure modes. Every peptide record now carries how it is obtained, what coverage looks like, how the grey market shows up, and a risk list.

A peptide without a manufacturer, a lot, and a label is a hypothesis in a bottle.Strand, Vol. 1